164 Screened Research Records Reveal Six Measurable Gaps in Health Plan Analytics Where Published Evidence Exists and No Tooling Has Been Built

InnoDexis has published its latest Innovation Intelligence Report covering health plan cost, coverage, data integrity and clinical AI governance, analyzing 164 screened research records published between September 2025 and September 2026, drawn from an initial corpus of 1,168 validated records across 32 named institutions. The report reveals that a substantial body of peer-reviewed evidence exists on what drives health plan cost, where members lose access to care, and where plan data systematically misrepresents plan populations — and that almost no software has been built against it.

Key Findings

The single largest evidence concentration — 50 of 164 records — addresses cost, coverage, reimbursement and network integrity using data that is public or already held by plans, with methods published in full. Medicaid managed care paid 25 percent less than Medicare plans and over 40 percent less than marketplace plans, derived from Transparency in Coverage files. Highest-markup hospitals are overwhelmingly for-profit and frequently deliver the lowest-value care on readmission and complication measures. Around 25 percent of Bell's palsy patients receive CT or MRI within 30 days of diagnosis against clinical guidelines.

A national study found that almost one in three enrolled Medicaid providers deliver no care to Medicaid beneficiaries — the provider directory records enrolment while claims record actual delivery, and reconciling them is a query on data plans already hold. Research on Medicare Advantage switching found that access to providers and dissatisfaction with care quality — not cost — are the primary drivers of plan switching, while only 33 percent of beneficiaries explored coverage options online.

Incomplete data carries a measured price. Omitting Medicare Advantage data from readmission measurement redistributes nearly $300 million annually in penalties across United States hospitals. Across five independent studies, self-harm history is coded at 22.6 percent of true prevalence, long COVID is identified in 16.3 percent of patients against a diagnostic code capture of under 7 percent, and illicit fentanyl use is inferred from routine records at more than double the medically coded rate. Extraction of structured facts from clinical text now reports 93 to 98 percent accuracy, making the undercount recoverable.

Population health surveillance latency fell from six to eighteen months to within one week in a Boston University study; quality measure review from months to seconds in a UC San Diego study on CMS sepsis measures. The boundary between retrospective audit and operational intervention is a latency problem, not a computation one.

A first-of-its-kind study found AI risk prediction tools in psychiatry produce higher false positive rates specifically for Black and Middle Eastern individuals, men, patients admitted by police and those with unstable housing. A fairness-constrained model for undiagnosed Alzheimer's reached 77 to 81 percent sensitivity across ethnic groups, where conventional models managed 39 to 53 percent — the constrained model was not merely fairer, it was substantially more accurate.

Strategic Insight and Trend Analysis

The defining pattern of this corpus is the gap between the evidence base and the tooling built against it. Cost and coverage research uses public data and published methods, yet plans below national scale generally lack the analytics capacity to execute it — exactly the gap a shared platform exists to close. The findings share a structurally useful property: they require new analytics on data a payer platform already handles rather than new data acquisition programmes. Network integrity uses claims and directory data. Low-value care detection uses claims against published guidelines. Budget impact modelling uses utilisation and pricing data.

The data integrity findings carry a commercial risk framing as much as a quality one. Every quality score, risk adjustment factor, care gap list and performance measure computed on a plan's behalf is exposed to the same failure mode the Michigan readmission study documents: a precise, confident, wrong answer that redistributes real money and is invisible from inside the calculation. The conditions most likely to be missing from coded data are stigmatised, chronic, poorly reimbursed or newly defined — disproportionately the conditions that drive avoidable utilisation. A risk model trained on coded data systematically under-weights precisely the drivers a plan most needs to see.

The federated learning findings remove the two principal objections to multi-plan scale advantage. MIT demonstrated roughly 81 percent faster training than standard federated learning with 80 percent lower memory overhead. Columbia's framework permits joint model training without first harmonising tenants to a common clinical vocabulary — normally the longest task in any multi-tenant analytics programme. Each additional plan improves model quality for all, a genuine network effect rather than a shared-cost argument.

Global and Industry Implications

For corporates and R&D teams, the briefing's most immediately actionable finding is that the highest-leverage evidence fields are already populated: the reconciliation of directory enrolment against claims activity, extraction of structured clinical facts from notes at 93 to 98 percent accuracy, and continuous quality measure delivery. Each is achievable at marginal analytics cost on data the platform already handles, and none requires a new acquisition programme.

For investors and capital allocators, the trajectory modelling findings identify where risk stratification is systematically miscalibrated. Type 2 diabetes patients stratify into three ten-year BMI trajectories — 77.7 percent stable, 14.6 percent increasing, 7.7 percent decreasing — with differing outcomes, meaning programmes enrolling on a single risk threshold are spending against a population that behaves as several. Social, behavioural and environmental factors contributed as much as or more than genetic risk scores for four of six diseases studied at Mount Sinai.

For policymakers and national innovation bodies, three findings carry direct regulatory relevance. Network adequacy measured from provider directories is wrong by roughly a third, and the correct answer is computable from claims data plans already hold. AI risk tools producing documented false-positive concentration on vulnerable populations represent a defect that subgroup evaluation would catch before deployment. And prior authorisation was found to hinder access to lifesaving heart failure medications, establishing a basis for treating turnaround time and approval rates as member-outcome metrics rather than purely operational ones.

InnoDexis Statement

"Almost every finding in this evidence base is computable from data a plan already holds — the gap is not data acquisition but analytics capacity, and that is precisely the gap a shared platform exists to close," noted InnoDexis in its latest intelligence report.

Conclusion

The report closes with eight specific platform moves, each traced to a measured research finding: effective network computation from claims, population coverage as an explicit measure property, clinical text as a primary data source, continuous quality measurement, federated architecture as a platform default, subgroup evaluation in the standard model pipeline, trajectory-based risk stratification, and cost and coverage analytics as a plan-facing capability. Each is supported by a published effect size; none requires a new data source. The complete Executive Brief: Six Things the Evidence Already Shows is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a global Innovation Intelligence platform that tracks, analyzes, and interprets breakthrough innovations, prototypes, and emerging technologies across industries and countries. Its intelligence helps corporates, investors, and policymakers understand the true structure and direction of global innovation. Learn more at innodexis.ai.